[
  {
    "ts": null,
    "headline": "Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance",
    "summary": "Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's results. Click for this VYGR update.",
    "url": "https://finnhub.io/api/news?id=df0472f0d9bbaa3ae1653611aab840d47121551d78f2f5f5d1585eec4d644274",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738256764,
      "headline": "Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance",
      "id": 132501141,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2004780179/image_2004780179.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's results. Click for this VYGR update.",
      "url": "https://finnhub.io/api/news?id=df0472f0d9bbaa3ae1653611aab840d47121551d78f2f5f5d1585eec4d644274"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=71c91dac46d903ee3e4c5b67521125103905658ec693ec1fa47a7a1f2bf696c6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738254660,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 132521106,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=71c91dac46d903ee3e4c5b67521125103905658ec693ec1fa47a7a1f2bf696c6"
    }
  },
  {
    "ts": null,
    "headline": "Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside",
    "summary": "Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential opportunity. Click for more on TECX.",
    "url": "https://finnhub.io/api/news?id=6108b712518250bc0ecbb464c89424085bbce31f9667c8802e26347492f65294",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738248104,
      "headline": "Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside",
      "id": 132500642,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2021145398/image_2021145398.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential opportunity. Click for more on TECX.",
      "url": "https://finnhub.io/api/news?id=6108b712518250bc0ecbb464c89424085bbce31f9667c8802e26347492f65294"
    }
  },
  {
    "ts": null,
    "headline": "Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data",
    "summary": "Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=813f714acfa9378c145e3187e1ff78e9146f723c4186b24383fbf135dd9cf133",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738226235,
      "headline": "Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data",
      "id": 132499343,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2183489034/image_2183489034.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=813f714acfa9378c145e3187e1ff78e9146f723c4186b24383fbf135dd9cf133"
    }
  }
]